Tvardi Therapeutics, Inc. (NASDAQ:TVRD) Receives $55.50 Average Price Target from Brokerages

Tvardi Therapeutics, Inc. (NASDAQ:TVRD) has been assigned an average recommendation of “Moderate Buy” from the eight research firms that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation, three have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $55.50.

A number of equities research analysts have issued reports on the stock. Lucid Cap Mkts raised shares of Tvardi Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 4th. Wall Street Zen cut Tvardi Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, February 28th. Finally, Weiss Ratings reissued a “sell (e)” rating on shares of Tvardi Therapeutics in a report on Monday, December 29th.

Institutional Trading of Tvardi Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the company. Slate Path Capital LP bought a new position in shares of Tvardi Therapeutics in the second quarter worth $16,427,000. Vanguard Group Inc. boosted its stake in Tvardi Therapeutics by 5.2% during the third quarter. Vanguard Group Inc. now owns 419,167 shares of the company’s stock valued at $16,335,000 after buying an additional 20,757 shares during the period. American Financial Group Inc. purchased a new position in Tvardi Therapeutics during the fourth quarter worth about $962,000. 683 Capital Management LLC bought a new position in Tvardi Therapeutics in the 2nd quarter worth about $4,107,000. Finally, Vestal Point Capital LP purchased a new stake in shares of Tvardi Therapeutics in the 3rd quarter valued at about $6,508,000. 44.66% of the stock is currently owned by hedge funds and other institutional investors.

Tvardi Therapeutics Stock Up 2.0%

NASDAQ TVRD opened at $4.02 on Monday. The firm has a market cap of $37.71 million, a P/E ratio of -0.42 and a beta of 0.14. The company’s 50 day moving average is $4.08 and its 200-day moving average is $12.61. Tvardi Therapeutics has a 12-month low of $3.50 and a 12-month high of $43.65.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.